Kidney disease parameters, metabolic goal achievement, and arterial stiffness risk in Chinese adult people with type 2 diabetes.

2型糖尿病 brachial-ankle pulse wave velocity (baPWV) cardiovascular disease (CVD) estimated glomerular filtration rate (eGFR) metabolic goal type 2 diabetes urinary albumin-to-creatinine ratio (UACR) 代谢目标 估计肾小球滤过率(eGFR) 尿白蛋白/肌酐比值(UACR) 心血管疾病 臂-踝脉搏波传导速度(BaPWV)

Journal

Journal of diabetes
ISSN: 1753-0407
Titre abrégé: J Diabetes
Pays: Australia
ID NLM: 101504326

Informations de publication

Date de publication:
May 2022
Historique:
revised: 02 03 2022
received: 05 12 2021
accepted: 28 03 2022
pubmed: 6 5 2022
medline: 28 5 2022
entrez: 5 5 2022
Statut: ppublish

Résumé

To investigate the arterial stiffness (AS) risk within urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) categories and the joint effect between kidney disease parameters and metabolic goal achievement on AS risk in adult people with type 2 diabetes (T2D). A total of 27 439 Chinese participants with T2D from 10 National Metabolic Management Centers (MMC) were categorized into four albuminuria/decreased eGFR groups. The criteria for decreased eGFR and AS were eGFR <90 ml/min/1.73 m After full adjustment, odds ratios (ORs) for AS were highest for albuminuria and decreased eGFR (2.23 [1.98-2.52]) and were higher for albuminuria and normal eGFR (1.52 [1.39-1.67]) than for those with nonalbuminuria and decreased eGFR (1.17 [1.04-1.32]). Both UACR and eGFR in the subgroup or overall population independently correlated with AS risk. The achievement of ≥2 metabolic goals counteracted the association between albuminuria and AS risk (OR: 0.93; 95% CI: 0.80-1.07; p = .311). When the metabolic goals added up to ≥2 for patients with decreased eGFR, they showed significantly lower AS risk (OR: 0.65; 95% CI: 0.56-0.74; p < .001). Both higher UACR and lower eGFR are determinants of AS risk, with UACR more strongly related to AS than eGFR in adults with T2D. The correlation between albuminuria/decreased eGFR and AS was modified by the achievement of multiple metabolic elements. 背景: 探讨成人2型糖尿病(T2D)患者尿白蛋白/肌酐(UACR)和估计肾小球滤过率(eGFR)两类指标对动脉硬化(AS)风险的影响, 以及肾脏疾病和代谢目标实现程度对AS风险的联合影响。 方法: 将来自10个国家代谢管理中心(MMC)的27439名T2D受试者分为4个白蛋白尿/eGFR降低组。以eGFR<90ml/min/1.73m

Sections du résumé

BACKGROUND BACKGROUND
To investigate the arterial stiffness (AS) risk within urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) categories and the joint effect between kidney disease parameters and metabolic goal achievement on AS risk in adult people with type 2 diabetes (T2D).
METHODS METHODS
A total of 27 439 Chinese participants with T2D from 10 National Metabolic Management Centers (MMC) were categorized into four albuminuria/decreased eGFR groups. The criteria for decreased eGFR and AS were eGFR <90 ml/min/1.73 m
RESULTS RESULTS
After full adjustment, odds ratios (ORs) for AS were highest for albuminuria and decreased eGFR (2.23 [1.98-2.52]) and were higher for albuminuria and normal eGFR (1.52 [1.39-1.67]) than for those with nonalbuminuria and decreased eGFR (1.17 [1.04-1.32]). Both UACR and eGFR in the subgroup or overall population independently correlated with AS risk. The achievement of ≥2 metabolic goals counteracted the association between albuminuria and AS risk (OR: 0.93; 95% CI: 0.80-1.07; p = .311). When the metabolic goals added up to ≥2 for patients with decreased eGFR, they showed significantly lower AS risk (OR: 0.65; 95% CI: 0.56-0.74; p < .001).
CONCLUSIONS CONCLUSIONS
Both higher UACR and lower eGFR are determinants of AS risk, with UACR more strongly related to AS than eGFR in adults with T2D. The correlation between albuminuria/decreased eGFR and AS was modified by the achievement of multiple metabolic elements.
背景: 探讨成人2型糖尿病(T2D)患者尿白蛋白/肌酐(UACR)和估计肾小球滤过率(eGFR)两类指标对动脉硬化(AS)风险的影响, 以及肾脏疾病和代谢目标实现程度对AS风险的联合影响。 方法: 将来自10个国家代谢管理中心(MMC)的27439名T2D受试者分为4个白蛋白尿/eGFR降低组。以eGFR<90ml/min/1.73m

Autres résumés

Type: Publisher (chi)
背景: 探讨成人2型糖尿病(T2D)患者尿白蛋白/肌酐(UACR)和估计肾小球滤过率(eGFR)两类指标对动脉硬化(AS)风险的影响, 以及肾脏疾病和代谢目标实现程度对AS风险的联合影响。 方法: 将来自10个国家代谢管理中心(MMC)的27439名T2D受试者分为4个白蛋白尿/eGFR降低组。以eGFR<90ml/min/1.73m

Identifiants

pubmed: 35510608
doi: 10.1111/1753-0407.13269
pmc: PMC9366591
doi:

Substances chimiques

Creatinine AYI8EX34EU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

345-355

Informations de copyright

© 2022 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai JiaoTong University School of Medicine and John Wiley & Sons Australia, Ltd.

Références

Diabetes Care. 2011 May;34(5):e53; author reply e54
pubmed: 21525493
Am J Hypertens. 2015 Aug;28(8):958-65
pubmed: 25687879
J Am Soc Nephrol. 2005 Apr;16(4):1069-75
pubmed: 15743996
Circulation. 2004 Jan 20;109(2):184-9
pubmed: 14662706
Cardiovasc Diabetol. 2021 Apr 22;20(1):82
pubmed: 33888131
Front Cell Dev Biol. 2019 Dec 03;7:314
pubmed: 31850348
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Am Soc Nephrol. 2005 Apr;16(4):1141-8
pubmed: 15743997
Diabetes Care. 1998 Dec;21(12):2191-2
pubmed: 9839117
J Diabetes. 2022 May;14(5):345-355
pubmed: 35510608
Am J Hypertens. 2016 Sep;29(9):1038-45
pubmed: 27068705
J Am Soc Nephrol. 2007 Jun;18(6):1942-52
pubmed: 17460143
Nephrol Dial Transplant. 2021 Jan 25;36(2):281-288
pubmed: 31532488
Am J Kidney Dis. 2019 Feb;73(2):240-247
pubmed: 29908694
Am J Kidney Dis. 2010 Jan;55(1):21-30
pubmed: 19765871
Lancet Diabetes Endocrinol. 2015 Jul;3(7):514-25
pubmed: 26028594
Kidney Int. 2004 Jul;66(1):448-54
pubmed: 15200455
Am J Kidney Dis. 2018 Nov;72(5):682-690
pubmed: 30007506
J Hum Hypertens. 2005 Jun;19(6):439-44
pubmed: 15660121
Diabetes Care. 2015 May;38(5):905-12
pubmed: 25710922
J Am Soc Nephrol. 2009 Sep;20(9):2044-53
pubmed: 19608701
Diabetes Care. 2000 Aug;23(8):1108-12
pubmed: 10937506
Curr Med Res Opin. 2003;19(1):22-7
pubmed: 12661776
Circulation. 1983 Jul;68(1):50-8
pubmed: 6851054
BMJ Open Diabetes Res Care. 2020 Oct;8(1):
pubmed: 33087340
Nephrol Dial Transplant. 2011 Sep;26(9):2820-7
pubmed: 21335440
J Diabetes. 2019 Jan;11(1):11-13
pubmed: 30284373
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
PLoS One. 2019 Feb 4;14(2):e0210522
pubmed: 30716076
Ann Biol Clin (Paris). 2018 Feb 1;77(1):26-35
pubmed: 30799295
Hypertens Res. 2003 Aug;26(8):615-22
pubmed: 14567500
Diabet Med. 1992 Mar;9(2):114-9
pubmed: 1563244
Atherosclerosis. 2010 Jul;211(1):315-21
pubmed: 20226463
Curr Hypertens Rep. 2004 Dec;6(6):436-41
pubmed: 15527687
Diabetes Care. 2020 Jan;43(1):122-129
pubmed: 31796570
J Formos Med Assoc. 2018 Aug;117(8):662-675
pubmed: 29486908

Auteurs

Chen Xu (C)

Department of Endocrinology and Metabolism, People's Hospital of Zhengzhou Affiliated Henan University of Chinese Medicine, Zhengzhou, China.

Li Li (L)

Department of Endocrinology and Metabolism, People's Hospital of Zhengzhou Affiliated Henan University of Chinese Medicine, Zhengzhou, China.

Juan Shi (J)

Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the P.R. China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Bangqun Ji (B)

Department of Endocrinology, Xingyi People's Hospital, Xingyi, China.

Qidong Zheng (Q)

Department of Internal medicine, The Second People's Hospital of Yuhuan, Yuhuan, China.

Yufan Wang (Y)

Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Tingyu Ke (T)

Department of Endocrinology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.

Li Li (L)

Department of Endocrinology, Ningbo First Hospital, Ningbo, China.

Dong Zhao (D)

Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China.

Yuancheng Dai (Y)

Department of Internal medicine of traditional Chinese medicine, Sheyang Diabetes Hospital, Yancheng, China.

Fengmei Xu (F)

Department of Endocrinology and Metabolism, Hebi Coal (Group), LTD, General Hospital, Hebi, China.

Ying Peng (Y)

Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the P.R. China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Yifei Zhang (Y)

Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the P.R. China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Qijuan Dong (Q)

Department of Endocrinology and Metabolism, People's Hospital of Zhengzhou Affiliated Henan University of Chinese Medicine, Zhengzhou, China.

Weiqing Wang (W)

Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the P.R. China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH